

## References

### I-9004

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/>
2. Nplate prescribing information. Amgen. January 2021.
3. Neunert C, Terrell DR, Arnold DM, et al. The American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood* 2019; volume 3 number 23: 3829-3866.
4. National Institute for Health and Care Excellence (2014): Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
5. Johns Hopkins Bloomberg School of Public Health. Center for Health Security. Clinicians' Biosecurity News. Analysis of Advances and Challenges in Clinical Biosecurity. April 2011.
6. CDC Centers for Disease Control and Prevention. Radiation Emergencies. Acute Radiation Syndrome: A Fact Sheet for Clinicians. Accessed at: <https://www.cdc.gov/nceh/radiation/emergencies/arsphysicianfactsheet.htm>